Publications 2024

Grindedal EM, Zucknick M, Stormorken A, Rønne E, Tandstad NM, Isaacs WB, Axcrona K, Mæhle L (2024)
Outcomes of 10 years of PSA screening for prostate cancer in Norwegian men with Lynch syndrome
Prostate (in press)
DOI 10.1002/pros.24711, PubMed 38629217

Hendricks LAJ, Verbeek KCJ, Schuurs-Hoeijmakers JHM, Mensenkamp AR, Brems H, de Putter R, Anastasiadou VC, Villy MC, Jahn A, Steinke-Lange V, Baldassarri M, Irmejs A, de Jong MM, Links TP, Leter EM, Bosch DGM, Høberg-Vetti H, Tveit Haavind M, Jørgensen K, Mæhle L, Blatnik A, Brunet J, Darder E, Tham E, Hoogerbrugge N et al. (2024)
Lifestyle Factors and Breast Cancer in Females with PTEN Hamartoma Tumor Syndrome (PHTS)
Cancers (Basel), 16 (5)
DOI 10.3390/cancers16050953, PubMed 38473316

Publications 2023

Wang A, Shen J, Rodriguez AA, Saunders EJ, Chen F, Janivara R, Darst BF, Sheng X, Xu Y, Chou AJ, Benlloch S, Dadaev T, Brook MN, Plym A, Sahimi A, Hoffman TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Laisk T, Figuerêdo J, Muir K, Ito S, Liu X et al. (2023)
Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants
Nat Genet, 55 (12), 2065-2074
DOI 10.1038/s41588-023-01534-4, PubMed 37945903

Publications 2022

Strømsvik N, Olsson P, Gravdehaug B, Lurås H, Schlichting E, Jørgensen K, Wangensteen T, Vamre T, Heramb C, Mæhle L, Grindedal EM (2022)
"It was an important part of my treatment": a qualitative study of Norwegian breast Cancer patients' experiences with mainstreamed genetic testing
Hered Cancer Clin Pract, 20 (1), 6
DOI 10.1186/s13053-022-00212-6, PubMed 35123550

Publications 2021

Bancroft EK, Page EC, Brook MN, Thomas S, Taylor N, Pope J, McHugh J, Jones AB, Karlsson Q, Merson S, Ong KR, Hoffman J, Huber C, Maehle L, Grindedal EM, Stormorken A, Evans DG, Rothwell J, Lalloo F, Brady AF, Bartlett M, Snape K, Hanson H, James P, McKinley J et al. (2021)
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study
Lancet Oncol, 22 (11), 1618-1631
DOI 10.1016/S1470-2045(21)00522-2, PubMed 34678156

Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, Schumacher FR, Olama AAA, Benlloch S, Dadaev T, Brook MN, Sahimi A, Hoffmann TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Muir K, Lophatananon A, Wan P, Le Marchand L, Wilkens LR, Stevens VL, Gapstur SM, Carter BD et al. (2021)
Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction
Nat Genet, 53 (1), 65-75
DOI 10.1038/s41588-020-00748-0, PubMed 33398198

Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, Schumacher FR, Olama AAA, Benlloch S, Dadaev T, Brook MN, Sahimi A, Hoffmann TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Muir K, Lophatananon A, Wan P, Le Marchand L, Wilkens LR, Stevens VL, Gapstur SM, Carter BD et al. (2021)
Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction
Nat Genet, 53 (3), 413
DOI 10.1038/s41588-021-00786-2, PubMed 33473200

Publications 2020

Grindedal EM, Jørgensen K, Olsson P, Gravdehaug B, Lurås H, Schlichting E, Vamre T, Wangensteen T, Heramb C, Mæhle L (2020)
Mainstreamed genetic testing of breast cancer patients in two hospitals in South Eastern Norway
Fam Cancer, 19 (2), 133-142
DOI 10.1007/s10689-020-00160-x, PubMed 32002722

Publications 2019

Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesseur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, Aldrich MC, Andrew AS, Andrulis IL, Anton-Culver H, Antoniou AC, Antonenkova NN, Arnold SM, Aronson KJ, Arun BK, Bandera EV et al. (2019)
Shared heritability and functional enrichment across six solid cancers
Nat Commun, 10 (1), 431
DOI 10.1038/s41467-018-08054-4, PubMed 30683880

Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesseur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, Aldrich MC, Andrew AS, Andrulis IL, Anton-Culver H, Antoniou AC, Antonenkova NN, Arnold SM, Aronson KJ, Arun BK, Bandera EV et al. (2019)
Publisher Correction: Shared heritability and functional enrichment across six solid cancers
Nat Commun, 10 (1), 4386
DOI 10.1038/s41467-019-12095-8, PubMed 31548585

Matejcic M, Saunders EJ, Dadaev T, Brook MN, Wang K, Sheng X, Olama AAA, Schumacher FR, Ingles SA, Govindasami K, Benlloch S, Berndt SI, Albanes D, Koutros S, Muir K, Stevens VL, Gapstur SM, Tangen CM, Batra J, Clements J, Gronberg H, Pashayan N, Schleutker J, Wolk A, West C et al. (2019)
Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry
Nat Commun, 10 (1), 382
DOI 10.1038/s41467-019-08293-z, PubMed 30655571

Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, Taylor N, Chamberlain A, Pope J, Raghallaigh HN, Evans DG, Rothwell J, Maehle L, Grindedal EM, James P, Mascarenhas L, McKinley J, Side L, Thomas T, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Jensen TD, Osther PJS et al. (2019)
Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers
Eur Urol, 76 (6), 831-842
DOI 10.1016/j.eururo.2019.08.019, PubMed 31537406

Schumacher FR, Olama AAA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM, Batra J et al. (2019)
Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
Nat Genet, 51 (2), 363
DOI 10.1038/s41588-018-0330-6, PubMed 30622367

Wangensteen T, Felde CN, Ahmed D, Mæhle L, Ariansen SL (2019)
Diagnostic mRNA splicing assay for variants in BRCA1 and BRCA2 identified two novel pathogenic splicing aberrations
Hered Cancer Clin Pract, 17, 14
DOI 10.1186/s13053-019-0113-9, PubMed 31143303

Publications 2018

Adams CD, Richmond R, Ferreira DLS, Spiller W, Tan V, Zheng J, Würtz P, Donovan J, Hamdy F, Neal D, Lane JA, Smith GD, Relton C, Eeles RA, Haiman CA, Kote-Jarai Z, Schumacher FR, Olama AAA, Benlloch S, Muir K, Berndt SI, Conti DV, Wiklund F, Chanock SJ, Gapstur S et al. (2018)
Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study
Cancer Epidemiol Biomarkers Prev, 28 (1), 208-216
DOI 10.1158/1055-9965.EPI-18-0079, PubMed 30352818

Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, Sheng X, Zhang Z, Muir K, Govindasami K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman P et al. (2018)
Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants
Nat Commun, 9 (1), 2256
DOI 10.1038/s41467-018-04109-8, PubMed 29892050

Heramb C, Wangensteen T, Grindedal EM, Ariansen SL, Lothe S, Heimdal KR, Mæhle L (2018)
BRCA1 and BRCA2 mutation spectrum - an update on mutation distribution in a large cancer genetics clinic in Norway
Hered Cancer Clin Pract, 16, 3
DOI 10.1186/s13053-017-0085-6, PubMed 29339979

Kaikkonen E, Rantapero T, Zhang Q, Taimen P, Laitinen V, Kallajoki M, Jambulingam D, Ettala O, Knaapila J, Boström PJ, Wahlström G, Sipeky C, Pursiheimo JP, Tammela T, Kellokumpu-Lehtinen PL, PRACTICAL Consortium, Fey V, Maehle L, Wiklund F, Wei GH, Schleutker J (2018)
ANO7 is associated with aggressive prostate cancer
Int J Cancer, 143 (10), 2479-2487
DOI 10.1002/ijc.31746, PubMed 30157291

Matejcic M, Saunders EJ, Dadaev T, Brook MN, Wang K, Sheng X, Olama AAA, Schumacher FR, Ingles SA, Govindasami K, Benlloch S, Berndt SI, Albanes D, Koutros S, Muir K, Stevens VL, Gapstur SM, Tangen CM, Batra J, Clements J, Gronberg H, Pashayan N, Schleutker J, Wolk A, West C et al. (2018)
Germline variation at 8q24 and prostate cancer risk in men of European ancestry
Nat Commun, 9 (1), 4616
DOI 10.1038/s41467-018-06863-1, PubMed 30397198

Mikropoulos C, Hutten Selkirk CG, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W et al. (2018)
Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition
Br J Cancer, 118 (6), e17
DOI 10.1038/bjc.2018.11, PubMed 29509747

Mikropoulos C, Selkirk CGH, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W et al. (2018)
Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition
Br J Cancer, 118 (2), 266-276
DOI 10.1038/bjc.2017.429, PubMed 29301143

Norum J, Grindedal EM, Heramb C, Karsrud I, Ariansen SL, Undlien DE, Schlichting E, Mæhle L (2018)
BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer
ESMO Open, 3 (3), e000328
DOI 10.1136/esmoopen-2018-000328, PubMed 29682331

Opsahl EM, Akslen LA, Schlichting E, Aas T, Brauckhoff K, Hagen AI, Rosenlund AF, Sigstad E, Grøholt KK, Mæhle L, Engebretsen LF, Jørgensen LH, Varhaug JE, Bjøro T (2018)
Trends in Diagnostics, Surgical Treatment, and Prognostic Factors for Outcomes in Medullary Thyroid Carcinoma in Norway: A Nationwide Population-Based Study
Eur Thyroid J, 8 (1), 31-40
DOI 10.1159/000493977, PubMed 30800639

Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM, Batra J et al. (2018)
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
Nat Genet, 50 (7), 928-936
DOI 10.1038/s41588-018-0142-8, PubMed 29892016

Publications 2017

Chen H, Ewing CM, Zheng S, Grindedaal EM, Cooney KA, Wiley K, Djurovic S, Andreassen OA, Axcrona K, Mills IG, Xu J, Maehle L, Fosså SD, Isaacs WB (2017)
Genetic factors influencing prostate cancer risk in Norwegian men
Prostate, 78 (3), 186-192
DOI 10.1002/pros.23453, PubMed 29181843

Grindedal EM, Heramb C, Karsrud I, Ariansen SL, Mæhle L, Undlien DE, Norum J, Schlichting E (2017)
Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers
BMC Cancer, 17 (1), 438
DOI 10.1186/s12885-017-3422-2, PubMed 28637432

Jarhelle E, Riise Stensland HM, Mæhle L, Van Ghelue M (2017)
Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort
Fam Cancer, 16 (1), 1-16
DOI 10.1007/s10689-016-9916-2, PubMed 27495310

Levin T, Mæhle L (2017)
Uptake of genetic counseling, genetic testing and surveillance in hereditary malignant melanoma (CDKN2A) in Norway
Fam Cancer, 16 (2), 257-265
DOI 10.1007/s10689-016-9939-8, PubMed 27804060

Publications 2016

Opsahl EM, Brauckhoff M, Schlichting E, Helset K, Svartberg J, Brauckhoff K, Mæhle L, Engebretsen LF, Sigstad E, Grøholt KK, Akslen LA, Jørgensen LH, Varhaug JE, Bjøro T (2016)
A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma
Thyroid, 26 (9), 1225-38
DOI 10.1089/thy.2015.0673, PubMed 27400880

Publications 2015

Heramb C, Ekstrøm PO, Tharmaratnam K, Hovig E, Møller P, Mæhle L (2015)
Ten modifiers of BRCA1 penetrance validated in a Norwegian series
Hered Cancer Clin Pract, 13 (1), 14
DOI 10.1186/s13053-015-0035-0, PubMed 26052370

Szulkin R, Karlsson R, Whitington T, Aly M, Gronberg H, Eeles RA, Easton DF, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Southey MC, FitzGerald LM, Henderson BE, Schumacher FR, Haiman CA, Sipeky C, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC et al. (2015)
Genome-wide association study of prostate cancer-specific survival
Cancer Epidemiol Biomarkers Prev, 24 (11), 1796-800
DOI 10.1158/1055-9965.EPI-15-0543, PubMed 26307654

Publications 2014

Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A et al. (2014)
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study
Eur Urol, 66 (3), 489-99
DOI 10.1016/j.eururo.2014.01.003, PubMed 24484606

Finch AP, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, Rosen B, Maehle L, Ghadirian P, Cybulski C, Huzarski T, Eisen A, Foulkes WD, Kim-Sing C, Ainsworth P, Tung N, Lynch HT, Neuhausen S, Metcalfe KA, Thompson I, Murphy J, Sun P, Narod SA (2014)
Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation
J Clin Oncol, 32 (15), 1547-53
DOI 10.1200/JCO.2013.53.2820, PubMed 24567435

Grindedal EM, Aarset H, Bjørnevoll I, Røyset E, Mæhle L, Stormorken A, Heramb C, Medvik H, Møller P, Sjursen W (2014)
The Norwegian PMS2 founder mutation c.989-1G > T shows high penetrance of microsatellite instable cancers with normal immunohistochemistry
Hered Cancer Clin Pract, 12 (1), 12
DOI 10.1186/1897-4287-12-12, PubMed 24790682

Møller P, Stormorken A, Holmen MM, Hagen AI, Vabø A, Mæhle L (2014)
The clinical utility of genetic testing in breast cancer kindreds: a prospective study in families without a demonstrable BRCA mutation
Breast Cancer Res Treat, 144 (3), 607-14
DOI 10.1007/s10549-014-2902-1, PubMed 24619173

Publications 2013

Geisler J, Bachmann IM, Nyakas M, Helsing P, Fjøsne HE, Mæhle LO, Aamdal S, Eide NA, Svendsen HL, Straume O, Robsahm TE, Jacobsen KD, Akslen LA (2013)
Malignant melanoma--diagnosis, treatment and follow-up in Norway
Tidsskr Nor Laegeforen, 133 (20), 2154-9
DOI 10.4045/tidsskr.12.1416, PubMed 24172628

Hagen AI, Mæhle L, Vedå N, Vetti HH, Stormorken A, Ludvigsen T, Guntvedt B, Isern AE, Schlichting E, Kleppe G, Bofin A, Gullestad HP, Møller P (2013)
Risk reducing mastectomy, breast reconstruction and patient satisfaction in Norwegian BRCA1/2 mutation carriers
Breast, 23 (1), 38-43
DOI 10.1016/j.breast.2013.10.002, PubMed 24210736

Møller P, Stormorken A, Jonsrud C, Holmen MM, Hagen AI, Clark N, Vabø A, Sun P, Narod SA, Mæhle L (2013)
Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program
Breast Cancer Res Treat, 139 (1), 155-61
DOI 10.1007/s10549-013-2540-z, PubMed 23615785

Publications 2012

Bailey-Wilson JE, Childs EJ, Cropp CD, Schaid DJ, Xu J, Camp NJ, Cannon-Albright LA, Farnham JM, George A, Powell I, Carpten JD, Giles GG, Hopper JL, Severi G, English DR, Foulkes WD, Mæhle L, Møller P, Eeles R, Easton D, Guy M, Edwards S, Badzioch MD, Whittemore AS, Oakley-Girvan I et al. (2012)
Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families
BMC Med Genet, 13, 46
DOI 10.1186/1471-2350-13-46, PubMed 22712434

Møller P, Maehle L, Vabø A, Clark N, Sun P, Narod SA (2012)
Age-specific incidence rates for breast cancer in carriers of BRCA1 mutations from Norway
Clin Genet, 83 (1), 88-91
DOI 10.1111/j.1399-0004.2012.01855.x, PubMed 22320316

Publications 2011

Lu L, Cancel-Tassin G, Valeri A, Cussenot O, Lange EM, Cooney KA, Farnham JM, Camp NJ, Cannon-Albright LA, Tammela TL, Schleutker J, Hoegel J, Herkommer K, Maier C, Vogel W, Wiklund F, Emanuelsson M, Grönberg H, Wiley KE, Isaacs SD, Walsh PC, Helfand BT, Kan D, Catalona WJ, Stanford JL et al. (2011)
Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG
Prostate, 72 (4), 410-26
DOI 10.1002/pros.21443, PubMed 21748754

Møller P, Clark N, Mæhle L (2011)
A SImplified method for Segregation Analysis (SISA) to determine penetrance and expression of a genetic variant in a family
Hum Mutat, 32 (5), 568-71
DOI 10.1002/humu.21441, PubMed 21309035

Publications 2010

Bodd TL, Van Ghelue M, Eiklid K, Ruud E, Møller P, Mæhle L (2010)
Fanconi anaemia, BRCA2 and familial considerations - follow up on a previous case report
Acta Paediatr, 99 (11), 1741-3
DOI 10.1111/j.1651-2227.2010.01929.x, PubMed 20608899

Christensen GB, Baffoe-Bonnie AB, George A, Powell I, Bailey-Wilson JE, Carpten JD, Giles GG, Hopper JL, Severi G, English DR, Foulkes WD, Maehle L, Moller P, Eeles R, Easton D, Badzioch MD, Whittemore AS, Oakley-Girvan I, Hsieh CL, Dimitrov L, Xu J, Stanford JL, Johanneson B, Deutsch K, McIntosh L et al. (2010)
Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses
Prostate, 70 (7), 735-44
DOI 10.1002/pros.21106, PubMed 20333727

Mitra AV, Bancroft EK, Barbachano Y, Page EC, Foster CS, Jameson C, Mitchell G, Lindeman GJ, Stapleton A, Suthers G, Evans DG, Cruger D, Blanco I, Mercer C, Kirk J, Maehle L, Hodgson S, Walker L, Izatt L, Douglas F, Tucker K, Dorkins H, Clowes V, Male A, Donaldson A et al. (2010)
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study
BJU Int, 107 (1), 28-39
DOI 10.1111/j.1464-410X.2010.09648.x, PubMed 20840664

Møller P, Mæhle L, Engebretsen LF, Ludvigsen T, Jonsrud C, Apold J, Vabø A, Clark N (2010)
High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series
Hered Cancer Clin Pract, 8 (1), 2
DOI 10.1186/1897-4287-8-2, PubMed 20180971

Sjursen W, Haukanes BI, Grindedal EM, Aarset H, Stormorken A, Engebretsen LF, Jonsrud C, Bjørnevoll I, Andresen PA, Ariansen S, Lavik LA, Gilde B, Bowitz-Lothe IM, Maehle L, Møller P (2010)
Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers
J Med Genet, 47 (9), 579-85
DOI 10.1136/jmg.2010.077677, PubMed 20587412

Publications 2009

Grindedal EM, Møller P, Eeles R, Stormorken AT, Bowitz-Lothe IM, Landrø SM, Clark N, Kvåle R, Shanley S, Maehle L (2009)
Germ-line mutations in mismatch repair genes associated with prostate cancer
Cancer Epidemiol Biomarkers Prev, 18 (9), 2460-7
DOI 10.1158/1055-9965.EPI-09-0058, PubMed 19723918

Grindedal EM, Renkonen-Sinisalo L, Vasen H, Evans G, Sala P, Blanco I, Gronwald J, Apold J, Eccles DM, Sánchez AA, Sampson J, Järvinen HJ, Bertario L, Crawford GC, Stormorken AT, Maehle L, Moller P (2009)
Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds
J Med Genet, 47 (2), 99-102
DOI 10.1136/jmg.2009.068130, PubMed 19635727

Hagen AI, Tretli S, Maehle L, Apold J, Vedå N, Møller P (2009)
Survival in Norwegian BRCA1 mutation carriers with breast cancer
Hered Cancer Clin Pract, 7 (1), 7
DOI 10.1186/1897-4287-7-7, PubMed 19366445

Publications 2008

Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Østenstad B, Lundgren S, Berge EO, Risberg T, Mjaaland I, Maehle L, Engebretsen LF, Lillehaug JR, Lønning PE (2008)
CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer
PLoS One, 3 (8), e3062
DOI 10.1371/journal.pone.0003062, PubMed 18725978

Evans DG, Baildam AD, Anderson E, Brain A, Shenton A, Vasen HF, Eccles D, Lucassen A, Pichert G, Hamed H, Moller P, Maehle L, Morrison PJ, Stoppat-Lyonnet D, Gregory H, Smyth E, Niederacher D, Nestle-Krämling C, Campbell J, Hopwood P, Lalloo F, Howell A (2008)
Risk reducing mastectomy: outcomes in 10 European centres
J Med Genet, 46 (4), 254-8
DOI 10.1136/jmg.2008.062232, PubMed 18996907

Evans DG, Gaarenstroom KN, Stirling D, Shenton A, Maehle L, Dørum A, Steel M, Lalloo F, Apold J, Porteous ME, Vasen HF, van Asperen CJ, Moller P (2008)
Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers
J Med Genet, 46 (9), 593-7
DOI 10.1136/jmg.2008.058248, PubMed 18413372

Grindedal EM, Blanco I, Stormorken A, Maehle L, Clark N, González S, Capella G, Vasen H, Burn J, Møller P (2008)
High risk of endometrial cancer in colorectal cancer kindred is pathognomonic for MMR-mutation carriers
Fam Cancer, 8 (2), 145-51
DOI 10.1007/s10689-008-9219-3, PubMed 18841495

Helsing P, Nymoen DA, Ariansen S, Steine SJ, Maehle L, Aamdal S, Langmark F, Loeb M, Akslen LA, Molven A, Andresen PA (2008)
Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas
Genes Chromosomes Cancer, 47 (2), 175-84
DOI 10.1002/gcc.20518, PubMed 18023021

Maehle L, Apold J, Paulsen T, Hagen B, Løvslett K, Fiane B, Van Ghelue M, Clark N, Møller P (2008)
High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers
Clin Cancer Res, 14 (22), 7569-73
DOI 10.1158/1078-0432.CCR-08-0112, PubMed 19010876

Norum J, Hagen AI, Maehle L, Apold J, Burn J, Møller P (2008)
Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis
Eur J Cancer, 44 (7), 963-71
DOI 10.1016/j.ejca.2008.02.025, PubMed 18362067

Publications 2007

Camp NJ, Cannon-Albright LA, Farnham JM, Baffoe-Bonnie AB, George A, Powell I, Bailey-Wilson JE, Carpten JD, Giles GG, Hopper JL, Severi G, English DR, Foulkes WD, Maehle L, Moller P, Eeles R, Easton D, Badzioch MD, Whittemore AS, Oakley-Girvan I, Hsieh CL, Dimitrov L, Xu J, Stanford JL, Johanneson B et al. (2007)
Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics
Hum Mol Genet, 16 (11), 1271-8
DOI 10.1093/hmg/ddm075, PubMed 17478474

Hagen AI, Bofin AM, Ytterhus B, Maehle LO, Kjellevold KH, Myhre HO, Møller P, Lønning PE (2007)
Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations
Acta Oncol, 46 (2), 199-203
DOI 10.1080/02841860600949552, PubMed 17453369

Hagen AI, Kvistad KA, Maehle L, Holmen MM, Aase H, Styr B, Vabø A, Apold J, Skaane P, Møller P (2007)
Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series
Breast, 16 (4), 367-74
DOI 10.1016/j.breast.2007.01.006, PubMed 17317184

Moller P, Evans DG, Reis MM, Gregory H, Anderson E, Maehle L, Lalloo F, Howell A, Apold J, Clark N, Lucassen A, Steel CM (2007)
Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status
Int J Cancer, 121 (5), 1017-20
DOI 10.1002/ijc.22789, PubMed 17471561

Møller P, Hagen AI, Apold J, Maehle L, Clark N, Fiane B, Løvslett K, Hovig E, Vabø A (2007)
Genetic epidemiology of BRCA mutations--family history detects less than 50% of the mutation carriers
Eur J Cancer, 43 (11), 1713-7
DOI 10.1016/j.ejca.2007.04.023, PubMed 17574839

Møller P, Maehle L, Clark N, Apold J (2007)
No sib pair concordance for breast or ovarian cancer in BRCA1 mutation carriers
Hered Cancer Clin Pract, 5 (2), 67-71
DOI 10.1186/1897-4287-5-2-67, PubMed 19725986

Stormorken AT, Clark N, Grindedal E, Maehle L, Møller P (2007)
Prevention of colorectal cancer by colonoscopic surveillance in families with hereditary colorectal cancer
Scand J Gastroenterol, 42 (5), 611-7
DOI 10.1080/00365520601010230, PubMed 17454882

Publications 2006

Geirdal AØ, Maehle L, Heimdal K, Stormorken A, Møller P, Dahl AA (2006)
Quality of life and its relation to cancer-related stress in women of families with hereditary cancer without demonstrated mutation
Qual Life Res, 15 (3), 461-70
DOI 10.1007/s11136-005-3008-3, PubMed 16547785

Rustad CF, Bjørnslett M, Heimdal KR, Mæhle L, Apold J, Møller P (2006)
Germline PTEN mutations are rare and highly penetrant
Hered Cancer Clin Pract, 4 (4), 177-85
DOI 10.1186/1897-4287-4-4-177, PubMed 20223021

Publications 2005

Geirdal AØ, Reichelt JG, Dahl AA, Heimdal K, Maehle L, Stormorken A, Møller P (2005)
Psychological distress in women at risk of hereditary breast/ovarian or HNPCC cancers in the absence of demonstrated mutations
Fam Cancer, 4 (2), 121-6
DOI 10.1007/s10689-004-7995-y, PubMed 15951962

Hope Q, Bullock S, Evans C, Meitz J, Hamel N, Edwards SM, Severi G, Dearnaley D, Jhavar S, Southgate C, Falconer A, Dowe A, Muir K, Houlston RS, Engert JC, Roquis D, Sinnett D, Simard J, Heimdal K, Møller P, Maehle L, Badzioch M, Eeles RA, Easton DF, English DR et al. (2005)
Macrophage scavenger receptor 1 999C>T (R293X) mutation and risk of prostate cancer
Cancer Epidemiol Biomarkers Prev, 14 (2), 397-402
DOI 10.1158/1055-9965.EPI-04-0202, PubMed 15734964

Møller P, Maehle L, Apold J (2005)
[Hereditary breast cancer]
Tidsskr Nor Laegeforen, 125 (22), 3136-8
PubMed 16299574

Publications 2003

Heimdal K, Maehle L, Apold J, Pedersen JC, Møller P (2003)
The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer
Eur J Cancer, 39 (15), 2205-13
DOI 10.1016/s0959-8049(03)00548-3, PubMed 14522380

Publications 2002

Møller P, Borg A, Evans DG, Haites N, Reis MM, Vasen H, Anderson E, Steel CM, Apold J, Goudie D, Howell A, Lalloo F, Maehle L, Gregory H, Heimdal K (2002)
Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy
Int J Cancer, 101 (6), 555-9
DOI 10.1002/ijc.10641, PubMed 12237897

Publications 2001

Møller P, Borg A, Heimdal K, Apold J, Vallon-Christersson J, Hovig E, Maehle L, Norwegian Inherited Breast Cancer Group, Norwegian Inherited Ovarian Cancer Group (2001)
The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series
Eur J Cancer, 37 (8), 1027-32
DOI 10.1016/s0959-8049(01)00075-2, PubMed 11334729

Møller P, Heimdal K, Apold J, Fredriksen A, Borg A, Hovig E, Hagen A, Hagen B, Pedersen JC, Maehle L, Norwegian Inherited Breast Cancer Group, Norwegian Inherited Ovarian Cancer Group (2001)
Genetic epidemiology of BRCA1 mutations in Norway
Eur J Cancer, 37 (18), 2428-34
DOI 10.1016/s0959-8049(01)00299-4, PubMed 11720839

Publications 2000

Møller P, Apold J, Maehle L, Heimdal K (2000)
[European guidelines for health care in hereditary breast cancer]
Tidsskr Nor Laegeforen, 120 (6), 726-7
PubMed 10806889

Publications 1999

Borg A, Dørum A, Heimdal K, Maehle L, Hovig E, Møller P (1999)
BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations
Dis Markers, 15 (1-3), 79-84
DOI 10.1155/1999/278269, PubMed 10595257

Heimdal K, Apold J, Maehle L, Dørum A, Møller P (1999)
[Hereditary breast cancer in Norway]
Tidsskr Nor Laegeforen, 119 (26), 3929-32
PubMed 10592755

Heimdal K, Maehle L, Møller P (1999)
Costs and benefits of diagnosing familial breast cancer
Dis Markers, 15 (1-3), 167-73
DOI 10.1155/1999/751892, PubMed 10595273

Maehle L, Lystad E, Eilertsen E, Einarsdottír E, Høstmark AT, Haugen A (1999)
Growth of human lung adenocarcinoma in nude mice is influenced by various types of dietary fat and vitamin E
Anticancer Res, 19 (3A), 1649-55
PubMed 10470096

Moller P, Borg A, Evans G, Haites N, Steel CM, Vasen H, Gregory H, Hodgson S, Apold J, Lalloo F, Maehle L, Anderson E, Heimdal K, Biomed 2 Demonstration Programme I (1999)
Mutation-specific survival of inherited breast cancer
Dis. Markers, 15 (1-3), 205
DOI 10.1155/1999/902648

Moller P, Evans G, Anderson E, Maehle L, Lalloo F, Heimdal KR, Steel CM, Biomed 2 Demonstration Programme I (1999)
Use of cytology to diagnose inherited breast cancer
Dis. Markers, 15 (1-3), 206
DOI 10.1155/1999/909834

Møller P, Evans G, Haites N, Vasen H, Reis MM, Anderson E, Apold J, Hodgson S, Eccles D, Olsson H, Stoppa-Lyonnet D, Chang-Claude J, Morrison PJ, Bevilacqua G, Heimdal K, Maehle L, Lalloo F, Gregory H, Preece P, Borg A, Nevin NC, Caligo M, Steel CM (1999)
Guidelines for follow-up of women at high risk for inherited breast cancer: consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer
Dis Markers, 15 (1-3), 207-11
DOI 10.1155/1999/920109, PubMed 10595280

Møller P, Reis MM, Evans G, Vasen H, Haites N, Anderson E, Steel CM, Apold J, Lalloo F, Maehle L, Preece P, Gregory H, Heimdal K (1999)
Efficacy of early diagnosis and treatment in women with a family history of breast cancer. European Familial Breast Cancer Collaborative Group
Dis Markers, 15 (1-3), 179-86
DOI 10.1155/1999/805420, PubMed 10595275

Publications 1998

Moller P, Maehle L, Heimdal K, Dorum A, Apold J, Engebretsen LF, Kaurin RM, Jorgensen OG, Helgerud P, Qvist H, Bjorndal H, Kullmann G, Bohler P, Nysted A, Soreide JA, Varhaug JE, Aas T, Fjosne HE, Hagen A, Due J, Karesen R, Formoe E, Malme PA, Stedjeberg JO, Svenningsen SS et al. (1998)
Prospective findings in breast cancer kindreds: annual incidence rates according to age, stage at diagnosis, mean sojourn time, and incidence rates for contralateral cancer
Breast, 7 (1), 55-59
DOI 10.1016/S0960-9776(98)90053-4

Publications 1997

Dørum A, Møller P, Kamsteeg EJ, Scheffer H, Burton M, Heimdal KR, Maehle LO, Hovig E, Tropé CG, van der Hout AH, van der Meulen MA, Buys CH, te Meerman GJ (1997)
A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing
Eur J Cancer, 33 (14), 2390-2
DOI 10.1016/s0959-8049(97)00328-6, PubMed 9616287

Publications 1996

Mollerup S, Rivedal E, Mæhle L, Haugen A (1996)
Nickel(II) induces alterations in EGF- and TGF-beta 1-mediated growth control during malignant transformation of human kidney epithelial cells
Carcinogenesis, 17 (2), 361-7
DOI 10.1093/carcin/17.2.361, PubMed 8625464

Møller P, Maehle L, Heimdal K, Dørum A, Tretli S, Helgerud P, Quist H, Bjørndal H, Kåresen R, Nysted A, Varhaug JE, Fjøsne HE, Guleng RJ, Due J, Bøhler P, Giercksky KE, Tropé C, Kvinnsland S (1996)
Inherited breast carcinoma--prospective findings in 1,194 women at risk
Acta Oncol, 35 Suppl 8, 7-11
DOI 10.3109/02841869609098515, PubMed 9073043

Publications 1995

Maehle L, Eilertsen E, Mollerup S, Schønberg S, Krokan HE, Haugen A (1995)
Effects of n-3 fatty acids during neoplastic progression and comparison of in vitro and in vivo sensitivity of two human tumour cell lines
Br J Cancer, 71 (4), 691-6
DOI 10.1038/bjc.1995.136, PubMed 7710930

Publications 1994

Haugen A, Maehle L, Mollerup S, Rivedal E, Ryberg D (1994)
Nickel-induced alterations in human renal epithelial cells
Environ Health Perspect, 102 Suppl 3 (Suppl 3), 117-8
DOI 10.1289/ehp.94102s3117, PubMed 7843084

Publications 1992

Maehle L, Metcalf RA, Ryberg D, Bennett WP, Harris CC, Haugen A (1992)
Altered p53 gene structure and expression in human epithelial cells after exposure to nickel
Cancer Res, 52 (1), 218-21
PubMed 1727381